HRP20201998T1 - Makromolekule - Google Patents

Makromolekule Download PDF

Info

Publication number
HRP20201998T1
HRP20201998T1 HRP20201998TT HRP20201998T HRP20201998T1 HR P20201998 T1 HRP20201998 T1 HR P20201998T1 HR P20201998T T HRP20201998T T HR P20201998TT HR P20201998 T HRP20201998 T HR P20201998T HR P20201998 T1 HRP20201998 T1 HR P20201998T1
Authority
HR
Croatia
Prior art keywords
macromolecule
dendrimer
macromolecule according
group
pharmaceutically active
Prior art date
Application number
HRP20201998TT
Other languages
English (en)
Croatian (hr)
Inventor
David Owen
Brian Devlin Kelly
Peter Karellas
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of HRP20201998T1 publication Critical patent/HRP20201998T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Bipolar Transistors (AREA)
HRP20201998TT 2011-06-06 2012-06-06 Makromolekule HRP20201998T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161493886P 2011-06-06 2011-06-06
PCT/AU2012/000647 WO2012167309A1 (en) 2011-06-06 2012-06-06 Macromolecules
EP12797060.6A EP2729179B1 (en) 2011-06-06 2012-06-06 Macromolecules

Publications (1)

Publication Number Publication Date
HRP20201998T1 true HRP20201998T1 (hr) 2021-02-05

Family

ID=47295262

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201998TT HRP20201998T1 (hr) 2011-06-06 2012-06-06 Makromolekule

Country Status (18)

Country Link
US (2) US9744246B2 (forum.php)
EP (1) EP2729179B1 (forum.php)
JP (1) JP6158177B2 (forum.php)
KR (1) KR101941318B1 (forum.php)
CN (2) CN110124051B (forum.php)
AU (1) AU2012267200B2 (forum.php)
BR (1) BR112013031556B1 (forum.php)
CA (1) CA2837979C (forum.php)
DK (1) DK2729179T3 (forum.php)
ES (1) ES2834992T3 (forum.php)
HR (1) HRP20201998T1 (forum.php)
HU (1) HUE052285T2 (forum.php)
IN (1) IN2014DN00101A (forum.php)
LT (1) LT2729179T (forum.php)
PL (1) PL2729179T3 (forum.php)
PT (1) PT2729179T (forum.php)
SI (1) SI2729179T1 (forum.php)
WO (1) WO2012167309A1 (forum.php)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
WO2014184503A1 (fr) * 2013-05-16 2014-11-20 Universite De Strasbourg Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
EP3152248B1 (en) 2014-06-06 2019-10-09 Starpharma Pty Ltd Dendrimer-drug conjugates
AU2016305703B2 (en) 2015-08-11 2019-07-25 Coherent Biopharma I, Limited Multi-ligand drug conjugates and uses thereof
CN106554329B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性紫杉醇抗癌药物化合物及其制备方法和应用
CN106554330B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性多西他赛抗癌药物化合物及其制备方法和应用
WO2017068051A1 (en) * 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
WO2017135893A1 (en) * 2016-02-05 2017-08-10 Nipsea Technologies Pte Ltd Aqueous dendritic amine coatings
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
JP7249591B2 (ja) * 2018-03-29 2023-03-31 日油株式会社 分解性ポリエチレングリコール結合体
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
AU2019306745B2 (en) * 2018-07-19 2024-08-08 Starpharma Pty Ltd Therapeutic dendrimer
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
AU2019383466B2 (en) * 2018-11-20 2024-12-19 Starpharma Pty Ltd Therapeutic dendrimer
AU2019390489B2 (en) * 2018-11-29 2023-08-17 Starpharma Pty Ltd Dendrimer for therapy and imaging
KR20220052960A (ko) * 2019-08-28 2022-04-28 스타파마 피티와이 리미티드 표적화된 덴드리머 접합체
KR20220072851A (ko) * 2019-09-26 2022-06-02 스타파마 피티와이 리미티드 치료용 덴드리머
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
KR20230065935A (ko) * 2020-06-03 2023-05-12 스타파마 피티와이 리미티드 치료적 접합체
BR112023002855A2 (pt) 2020-08-25 2023-04-25 Shanghai Senhui Medicine Co Ltd Macromolécula carregada com fármaco e método de preparação para a mesma
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate
DK3973952T3 (da) * 2020-09-24 2024-03-18 Ocular Therapeutix Inc Bionedbrydelige intrakanalikulære indsatser med vedvarende frigivelse omfattende en hydrogel og cyclosporin
WO2022066891A1 (en) * 2020-09-24 2022-03-31 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent
CN117164357B (zh) * 2023-01-03 2024-07-19 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法
TW202448514A (zh) * 2023-05-08 2024-12-16 大陸商上海森輝醫藥有限公司 抗真菌藥的載藥大分子及其製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN101102787A (zh) * 2004-08-09 2008-01-09 艾丽奥斯生物制药有限公司 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CA2636599C (en) * 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
JP6084770B2 (ja) 2008-06-26 2017-02-22 プロリンクス エルエルシー 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
ES2584381T3 (es) * 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares

Also Published As

Publication number Publication date
SI2729179T1 (sl) 2021-01-29
US9744246B2 (en) 2017-08-29
DK2729179T3 (da) 2020-12-21
IN2014DN00101A (forum.php) 2015-05-15
EP2729179A4 (en) 2015-01-28
LT2729179T (lt) 2020-12-28
PL2729179T3 (pl) 2021-07-19
CN110124051B (zh) 2022-10-21
AU2012267200B2 (en) 2016-02-25
JP6158177B2 (ja) 2017-07-05
EP2729179A1 (en) 2014-05-14
BR112013031556B1 (pt) 2022-03-29
BR112013031556A2 (forum.php) 2017-08-29
JP2014520105A (ja) 2014-08-21
HUE052285T2 (hu) 2021-04-28
CA2837979C (en) 2021-03-30
CA2837979A1 (en) 2012-12-13
US10265409B2 (en) 2019-04-23
US20140171375A1 (en) 2014-06-19
CN103796684A (zh) 2014-05-14
PT2729179T (pt) 2020-11-25
ES2834992T3 (es) 2021-06-21
EP2729179B1 (en) 2020-09-23
KR101941318B1 (ko) 2019-01-22
CN110124051A (zh) 2019-08-16
AU2012267200A1 (en) 2013-05-09
US20170354739A1 (en) 2017-12-14
KR20140041678A (ko) 2014-04-04
CN103796684B (zh) 2019-06-25
HK1198356A1 (en) 2015-04-10
WO2012167309A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
HRP20201998T1 (hr) Makromolekule
Yang et al. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer
Noh et al. Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer
JP2014520105A5 (forum.php)
US10632131B2 (en) Controlled release system
JP7756185B2 (ja) ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
Guo et al. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance
Liang et al. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity
Lee et al. Paclitaxel-incorporated nanoparticles of hydrophobized polysaccharide and their antitumor activity
Taheri et al. The in vivo antitumor activity of LHRH targeted methotrexate–human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice
Du et al. Hyaluronic acid-functionalized half-generation of sectorial dendrimers for anticancer drug delivery and enhanced biocompatibility
Zheng et al. PCL-based thermo-gelling polymers for in vivo delivery of chemotherapeutics to tumors
WO2008136536A1 (ja) 化学架橋ヒアルロン酸誘導体を含むハイブリッドゲルおよびそれを用いた医薬組成物
Ye et al. Improved paclitaxel delivery with PEG-b-PLA/zein nanoparticles prepared via flash nanoprecipitation
TWI888483B (zh) 玻尿酸衍生物、醫藥組合物及玻尿酸衍生物－藥物結合體
Li et al. Polymeric complex micelles with double drug-loading strategies for folate-mediated paclitaxel delivery
CN106237340B (zh) 透明质酸纳米颗粒在制备治疗淋巴系统肿瘤的药物的用途
JP2011507838A5 (forum.php)
Yassine et al. Overview of the formulations and analogs in the taxanes' story
Huang et al. Monoclonal antibody-conjugated polyphosphoester-hyd-DOX prodrug nanoparticles for targeted chemotherapy of liver cancer cells
Yadav et al. Innovative nanoparticulate strategies in colon cancer treatment: a paradigm shift
WO2005079861A2 (en) Polymeric water soluble prodrugs
US20160317490A1 (en) Taxane- and Taxoid-Protein Compositions
Cai et al. Application of biodegradable microsphere injections: an anticancer perspective
Mai et al. PEG modified trimethyl chitosan based nanoparticles for the codelivery of doxorubicin and iSur-pDNA